Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections.
Researchers from Aligos Therapeutics Inc. have presented the discovery and preclinical evaluation of a novel next-generation liver targeted PD-L1 small molecule inhibitor, ALG-094103, which is being developed for the treatment of chronic hepatitis B and liver cancer.
It’s known that interferon-alpha (IFNα) activates interferon-stimulated genes (ISGs) and disrupts the hepatitis B virus (HBV) replication cycle. Pegylated (PEG)-IFNα has been widely used for its immunomodulatory and antiviral properties but it is not always well tolerated and thus its use is limited.
Gilead Sciences Inc. and Assembly Biosciences Inc. have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus on Assembly’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).
What CEO Jason Okazaki called Assembly Biosciences Inc.’s “monumental” deal for new antivirals with Gilead Sciences Inc. brings $100 million right away, consisting of an $84.8 million up-front payment and a $15.2 million equity investment. Wall Street liked it, and shares of South San Francisco-based Assembly (NASDAQ:ASMB) closed Oct. 17 at $1.25, up 52 cents or 72%, on word of the 12-year arrangement. Gilead (NASDAQ:GILD) ended at $80.48, up $1.28.
Epigenetic editing approach used the endogenous cellular mechanisms for regulating gene expression, leading to durable modulation of transcription without affecting the DNA sequence. Chroma Medicine Inc. scientists recently presented a novel epigenetic editing strategy for the treatment of chronic hepatitis B virus (HBV) infection.
Researchers from Assembly Biosciences Inc. recently presented details on the discovery and preclinical evaluation of a novel small-molecule hepatitis B virus (HBV) and hepatitis D virus (HDV) entry inhibitor, AB-1659.
The U.S. FDA recently convened an advisory hearing to discuss whether three in vitro diagnostics should be reclassified from class III to class II, including tests for the pathogens responsible for Hepatitis B and tuberculosis. The panel agreed that all three of the test types should be reshuffled to the lower-risk class II category, suggesting that test developers now have an opportunity to jump into a market with lower-cost tests that won’t need expensive and drawn-out clinical studies to obtain the FDA’s seal of approval.
